Profile data is unavailable for this security.
About the company
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
- Revenue in USD (TTM)25.52m
- Net income in USD-91.22m
- Incorporated2015
- Employees116.00
- LocationFoghorn Therapeutics Inc.500 Technology Square, Suite 700CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 586-3100
- Fax+1 (302) 655-5049
- Websitehttps://foghorntx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | 52.29m | -134.84m | 406.03m | 405.00 | -- | 10.40 | -- | 7.76 | -0.7079 | -0.7079 | 0.2696 | 0.1876 | 0.316 | -- | 8.98 | 129,113.60 | -81.48 | -26.09 | -112.69 | -31.04 | -- | -- | -257.86 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 411.94m | 52.00 | -- | 4.64 | -- | 41.55 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Perspective Therapeutics Inc | -3.68m | -53.78m | 416.03m | 116.00 | -- | 1.27 | -- | -- | -1.24 | -1.59 | -0.069 | 4.86 | -0.0147 | -- | -- | -31,741.38 | -21.44 | -- | -23.11 | -- | -- | -- | -- | -- | -- | -- | 0.0051 | -- | -- | -- | -- | -- | -- | -- |
| Allogene Therapeutics Inc | 43.00k | -283.43m | 429.83m | 232.00 | -- | 0.9261 | -- | 9,996.00 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 430.53m | 38.00 | -- | 538.31 | -- | 8.98 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Aura Biosciences Inc | 0.00 | -83.22m | 434.05m | 88.00 | -- | 2.49 | -- | -- | -1.73 | -1.73 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -43.22 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 436.96m | 116.00 | -- | -- | -- | 17.13 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Korro Bio Inc | 0.00 | -101.60m | 437.04m | 95.00 | -- | 2.44 | -- | -- | -17.04 | -17.04 | 0.00 | 19.28 | 0.00 | -- | -- | 0.00 | -70.10 | -31.55 | -76.20 | -36.48 | -- | -- | -- | -365.87 | -- | -104.93 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| 4D Molecular Therapeutics Inc | 18.00k | -143.48m | 437.06m | 201.00 | -- | 0.7908 | -- | 24,281.35 | -2.76 | -2.76 | 0.0004 | 10.63 | 0.00004 | -- | -- | 122.45 | -29.72 | -32.67 | -31.26 | -34.90 | -- | -- | -797,111.10 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 438.00m | 180.00 | -- | 1.67 | -- | 2.73 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Tango Therapeutics Inc | 43.38m | -123.40m | 438.26m | 140.00 | -- | 1.91 | -- | 10.10 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 439.77m | 150.00 | -- | 2.23 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| ACELYRIN Inc | 0.00 | -264.41m | 442.15m | 130.00 | -- | 0.8381 | -- | -- | -2.68 | -2.68 | 0.00 | 5.29 | 0.00 | -- | -- | 0.00 | -37.27 | -- | -41.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| MeiraGTx Holdings PLC | 13.93m | -88.18m | 449.21m | 389.00 | -- | 4.72 | -- | 32.25 | -1.30 | -1.30 | 0.2123 | 1.23 | 0.0492 | -- | 1.08 | 33,243.44 | -31.12 | -26.40 | -39.74 | -32.66 | -7.72 | -- | -633.05 | -420.70 | -- | -- | 0.4324 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| OmniAB Inc | 20.41m | -63.02m | 460.83m | 106.00 | -- | 1.61 | -- | 22.58 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.55m | -23.86m | 472.08m | 100.00 | -- | 5.10 | -- | 5.58 | -0.541 | -0.541 | 1.92 | 2.06 | 0.677 | 1.13 | 4.36 | 845,530.00 | -19.11 | -44.23 | -23.55 | -50.45 | 88.89 | -- | -28.22 | -181.13 | 3.54 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Foghorn Therapeutics Inc.'s reporting currency: US Dollar USD
37.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 6.33m | 11.45% |
| BVF Partners LPas of 30 Sep 2024 | 5.30m | 9.58% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 2024 | 2.30m | 4.15% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.69m | 3.05% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.65m | 2.98% |
| Euclidean Capital LLCas of 30 Sep 2024 | 1.57m | 2.84% |
| Geode Capital Management LLCas of 30 Sep 2024 | 677.39k | 1.22% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 505.95k | 0.91% |
| Point72 Asset Management LPas of 30 Sep 2024 | 399.70k | 0.72% |
| Birchview Capital LPas of 30 Sep 2024 | 320.93k | 0.58% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
